IP Library Granted Patent US 10,364,293
Granted Patent B2
US 10,364,293 · App. 15/310,585 · Granted Jul 30, 2019

Polypeptide binding to extracellular domain of epidermal growth factor receptor

Inventors: Hak-Sung Kim (Daejeon, KR); Joong-Jae Lee (Daejeon, KR)
Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
C07K16/30C07K14/195C07K14/46C07K14/71C07K19/00C12N15/62C12P21/02C07K2318/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,364,293
App. No.
15/310,585
Granted
Jul 30, 2019
Kind
B2
Abstract

The present invention relates to a polypeptide capable of binding specifically to the extracellular domain of epidermal growth factor receptor, a polynucleotide that encodes the polypeptide, an expression vector comprising the polynucleotide, a recombinant microorganism having the expression vector introduced therein, and a method of producing the polypeptide using the recombinant microorganism. The polypeptide according to the present invention can bind to the extracellular domain of epidermal growth factor receptor with a high binding affinity comparable to those of existing monoclonal antibodies that are widely used as targeted therapeutic agents, thereby inhibiting the activity of the epidermal growth factor receptor. The polypeptide is useful for the development of agents for the prevention or diseases associated with overexpression of epidermal growth factor receptor.

Claims (17)

1. A polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises the amino acid sequence of any one of SEQ ID NOS: 6 to 8.

2. The polypeptide of claim 1 , wherein the polypeptide has the ability to bind to the extracellular domain of epidermal growth factor receptor to inhibit the activity of the epidermal growth factor domain.

3. A polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises the amino acid sequence of any one of SEQ ID NOS: 6 to 8,

wherein the polypeptide comprises a fusion of the N-terminus of internalin B protein, a modified repeat module of variable lymphocyte receptor (VLR) protein, and the C-terminus of the VLR protein.

4. A polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises the amino acid sequence of any one of SEQ ID NOS: 6 to 8,

wherein the modified repeat module of the VLR protein comprises the following repeat module pattern:

LxxLxxLxLxxN (SEQ ID NO: 10)

wherein L is alanine, glycine, phenylalanine, tyrosine, leucine, isoleucine, valine, or tryptophan, N is asparagine, glutamine, seine, cysteine, or threonine, and x is any one of all 20 amino acids.

5. A polynucleotide that encodes the polypeptide of claim 1 .

6. A recombinant vector comprising the polynucleotide of claim 5 .

7. A recombinant microorganism having introduced therein the polynucleotide of claim 5 .

8. A recombinant microorganism having introduced therein the polynucleotide of claim 6 .

9. A method for producing a polypeptide binding specifically to epidermal growth factor receptor protein, comprising the steps of:

(i) culturing the recombinant microorganism of claim 7 to produce a polypeptide which has the ability to bind specifically to epidermal growth factor receptor protein and comprises an amino acid sequence of any one of SEQ ID NOS: 6 to 8; and

(ii) recovering the polypeptide of claim 1 from the cultured recombinant microorganism or the culture.

10. A composition for preventing or treating cancer, which comprises the polypeptide of claim 1 .

11. The composition of claim 10 , wherein the prevention or treatment of cancer is achieved by the binding of the polypeptide to epidermal growth factor receptor.

Assignments (3)
CHANGE OF NAME Recorded Nov 11, 2020
From: REPIGEN
To: PROEN THERAPEUTICS INC.
Reel/Frame 054388/0422 →
LICENSE Recorded Jun 17, 2019
From: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
To: REPIGEN
Reel/Frame 049488/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2016
From: KIM, HAK-SUNG; LEE, JOONG-JAE
To: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Reel/Frame 040780/0921 →
Priority Claims (1)
KR 10-2014-0062391 · May 23, 2014 · national
Continuity (1)
Related Publication 20170081422A1 · Mar 23, 2017